-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Zheng Aihua's research group, Institute of Zoology, Chinese Academy of Sciences, together with Qin Chengfeng's research group, Institute of Microbial Epidemiology, Academy of Military Medical Sciences, and Dr.
With the approval of several inactivated vaccines, mRNA vaccines, subunit vaccines and adenoviral vector vaccines, countries are working to increase vaccination rates
By replacing the G protein of VSV with the S protein of the new coronavirus, Zheng Aihua's research group constructed a replicable rVSV-SARS-CoV-2 vector vaccine and applied for a patent in March 2020
The SARS coronavirus is related to the new coronavirus.
These results lay the foundation for the development of rVSV-SARS-CoV/2-RBD as an effective vaccine candidate for SARS-CoV-2
Li Hongyue and Zhang Yuhang, graduate students of the Institute of Zoology, Chinese Academy of Sciences, Li Dong from Shenzhen Kangtai Biotechnology Co.
Paper link: https:// .
Figure 1: Schematic diagram of rVSV-SARS-CoV/2-RBD vaccine design
Figure 2: Protective effects of rVSV-SARS-CoV-2 and rVSV-SARS-CoV/2-RBD on hACE2 mice